Billion-Dollar M&A Surge in Pharma Sector During January

　　【Pharmaceutical Network Industry DynamicsIn 2024, the pharmaceutical industry is showing an increasingly heated trend in mergers and acquisitions. Recently, several domestic and international pharmaceutical companies, including Grand Pharmaceutical Group Limited, CSPC Innovation, Sanofi, and Johnson & Johnson, have announced acquisition deals. Most of these acquisitions aim to expand market presence and enrich product pipelines.
 

On January 15, Grand Pharmaceutical Group Limited announced that its subsidiary, Xi'an Beilin Pharmaceutical Co., Ltd. ("Xi'an Beilin"), recently reached a second acquisition agreement with Chongqing Duoputai Pharmaceutical Co., Ltd. ("Duoputai Pharmaceutical"). Upon fulfillment of relevant conditions, Xi'an Beilin will acquire 63% of the equity in Chongqing Duoputai Medical Technology Co., Ltd. ("Duoputai Medical Technology") for RMB 442.26 million.
 

On January 11, XenoPharm announced that the company is planning to issue shares and pay cash to purchase 100% of the equity of CSPC BAIKE BIOLOGICAL, and the stock has been suspended from trading starting January 11. This transaction is expected to constitute a major asset restructuring but does not constitute a backdoor listing. Public information shows that BAIKE BIOLOGICAL is a wholly-owned subsidiary of CSPC Group, specializing in the research and development, production, and sales of biological products, and serves as CSPC Group's large-scale biopharmaceutical industry base. The company currently has total assets of 2.64 billion yuan and fixed assets of 355 million yuan. It has more than seven new products under development, covering areas such as metabolism, respiratory system, allergies, and anti-tumor treatments. Once these projects reach full production, annual sales revenue is expected to exceed 10 billion yuan, with profits surpassing 2 billion yuan and taxes exceeding 1 billion yuan, demonstrating strong economic benefits.
 

　　……
 

Analysts believe that in recent years, a wave of pharmaceutical innovation and transformation has been rising in China. Against this backdrop, some companies with relatively sufficient cash flow have started frequent mergers and acquisitions to accelerate innovation and enrich their R&D pipelines. In 2024, China's biopharmaceutical market is expected to face a wave of acquisitions, and the types of mergers and acquisitions may also become more diversified.
 

Notably, compared to the situation in China, overseas pharmaceutical companies are also experiencing a very active wave of mergers and acquisitions, with even larger sums involved. Reportedly, in January this year, there were already several large-scale M&A cases in the global pharmaceutical market, involving leading global pharmaceutical companies such as Sanofi and Johnson & Johnson.
 

On January 23, Inhibrx and Sanofi announced that the two companies had entered into a definitive agreement under which Aventis, a subsidiary of Sanofi located in Pennsylvania, will acquire all assets and liabilities related to INBRX-101. In aggregate, the total value of the transaction is approximately $2.2 billion (equivalent to about 15.8 billion RMB), including the upfront cash portion, potential contingent value payments (if achieved), and the assumption of Inhibrx's debt. The boards of both Inhibrx and Sanofi have unanimously approved the deal, which is expected to close in Q2 2024.
 

On January 9, GlaxoSmithKline (GSK) announced that it had reached an acquisition agreement with Aiolos, a company focused on addressing respiratory and inflammatory diseases, to acquire the company's only pipeline, code-named AIO-001, a monoclonal antibody. For this, GSK will pay $1 billion upfront and $400 million upon successful regulatory milestones. Public information shows that through this acquisition, GSK will obtain Aiolos’ candidate drug, AIO-001 (SHR-1905). This candidate drug is a thymic stromal lymphopoietin (TSLP) monoclonal antibody independently developed by Hengrui and protected by intellectual property rights. Since the core assets of this company are derived from Hengrui Medicine, GSK will also be responsible for paying milestone payments based on success as well as tiered royalties to Hengrui Medicine.
 

On January 8, Johnson & Johnson announced that it would pay $2 billion in cash to acquire Ambrx Biopharma, a pharmaceutical company specializing in cancer treatments. Ambrx aims to target various cancers using antibody-drug conjugates (ADCs), which researchers describe as "guided missiles" capable of directly targeting and killing cancer cells while minimizing damage to healthy tissues. Under the terms of the deal, Johnson & Johnson will acquire Ambrx at $28 per share, approximately double the company’s closing price of $13.63 on Friday. The transaction is expected to be completed in the first half of 2024.
 

Overall, the current global pharmaceuticals and healthcare sector is experiencing active mergers and acquisitions (M&A) transaction activities. In terms of M&A focus, leading companies are prioritizing expansion in areas such as oncology, neuroscience, and rare diseases. Analysts predict that competition in innovative drugs within these fields will become increasingly intense in the future.
 

Disclaimer: Under no circumstances shall the information or opinions expressed in this article constitute investment advice to any person.